Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-21 in Stage IV Malignant Melanoma
NCT00336986Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2004
- Primary completion
- Oct 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human interleukin 21 in Malignant Melanoma (MM), sponsored by Novo Nordisk. Primary endpoint: Tumor size assessed according to international criteria at 8 weeks. Started Sep 2004; status: completed.
02
Drugs
recombinant human interleukin 21
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00336986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336986.